ProCE Banner Activity

RET and NTRK Genomic Aberrations in Lung and Thyroid Cancer: A Resource for Healthcare Professionals

PDF

Download this PDF resource for an overview of the role of alterations in RET and NTRK in the development of lung and thyroid cancer, including guidance on molecular testing and the latest clinical data supporting the use of RET and TRK inhibitor therapy in the management of these diseases.

Released: November 14, 2022

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc, Blueprint Medicines and Genentech, a member of the Roche Group, and Lilly.

Bayer HealthCare Pharmaceuticals Inc.

Blueprint Medicines and Genentech, a member of the Roche Group

Lilly

Partners

American Society for Clinical Pathology

ProCE Banner

Partnered with the American Society for Clinical Pathology.